IL217746A - Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation - Google Patents

Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation

Info

Publication number
IL217746A
IL217746A IL217746A IL21774612A IL217746A IL 217746 A IL217746 A IL 217746A IL 217746 A IL217746 A IL 217746A IL 21774612 A IL21774612 A IL 21774612A IL 217746 A IL217746 A IL 217746A
Authority
IL
Israel
Prior art keywords
aureus
prevention
treatment
monoclonal antibody
antibody against
Prior art date
Application number
IL217746A
Other languages
English (en)
Hebrew (he)
Other versions
IL217746A0 (en
Original Assignee
Aridis Pharmaceuticals Inc
Kenta Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aridis Pharmaceuticals Inc, Kenta Biotech Ag filed Critical Aridis Pharmaceuticals Inc
Publication of IL217746A0 publication Critical patent/IL217746A0/en
Publication of IL217746A publication Critical patent/IL217746A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL217746A 2009-08-10 2012-01-26 Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation IL217746A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09010311A EP2284193A1 (en) 2009-08-10 2009-08-10 Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
US26633009P 2009-12-03 2009-12-03
PCT/EP2010/004884 WO2011018208A1 (en) 2009-08-10 2010-08-10 Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation

Publications (2)

Publication Number Publication Date
IL217746A0 IL217746A0 (en) 2012-03-29
IL217746A true IL217746A (en) 2016-05-31

Family

ID=41381987

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217746A IL217746A (en) 2009-08-10 2012-01-26 Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation

Country Status (11)

Country Link
US (1) US9249215B2 (enExample)
EP (3) EP2284193A1 (enExample)
JP (1) JP6064241B2 (enExample)
KR (1) KR101836130B1 (enExample)
CN (1) CN102549013B (enExample)
CA (1) CA2769394C (enExample)
ES (2) ES2529175T3 (enExample)
IL (1) IL217746A (enExample)
IN (1) IN2012DN00797A (enExample)
RU (1) RU2529946C9 (enExample)
WO (1) WO2011018208A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140286960A1 (en) * 2011-07-28 2014-09-25 Cangene Corporation Staphlococcus aureus alpha-hemolysin antibodies
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US9914767B2 (en) 2012-04-17 2018-03-13 Arsanis Biosciences Gmbh Cross-reactive Staphylococcus aureus antibody
ES2912267T3 (es) 2012-11-06 2022-05-25 Medimmune Llc Métodos de tratamiento de enfermedades asociadas a S. aureus
EP2917360B1 (en) * 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
CN104211804A (zh) * 2014-08-20 2014-12-17 钱泓 一种抗金黄色葡萄球菌多克隆抗体的制备与应用
TW202311284A (zh) * 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
JP7680967B2 (ja) * 2019-06-14 2025-05-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｐｄ－１に対する抗体およびその使用方法
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
CN113444172A (zh) * 2020-03-25 2021-09-28 兴盟生物医药(苏州)有限公司 金黄色葡萄球菌α-毒素特异性抗体及其应用
US20230374114A1 (en) * 2020-04-16 2023-11-23 Dana-Farber Cancer Institute, Inc. Coronavirus antibodies and methods of use thereof
WO2021233408A1 (zh) * 2020-05-21 2021-11-25 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
WO2023208123A1 (zh) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288214B1 (en) * 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
DK2027155T3 (en) * 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
JP2009539979A (ja) 2006-06-12 2009-11-19 ナビ バイオファーマシューティカルズ ブドウ球菌感染症を治療および予防するための、α毒素の使用
KR20100072228A (ko) * 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물

Also Published As

Publication number Publication date
JP2013501506A (ja) 2013-01-17
JP6064241B2 (ja) 2017-01-25
EP2464665B1 (en) 2014-12-03
EP2860191A1 (en) 2015-04-15
CN102549013A (zh) 2012-07-04
CA2769394A1 (en) 2011-02-17
KR20120047270A (ko) 2012-05-11
KR101836130B1 (ko) 2018-03-08
US20120201829A1 (en) 2012-08-09
IN2012DN00797A (enExample) 2015-06-26
IL217746A0 (en) 2012-03-29
CN102549013B (zh) 2015-05-06
RU2529946C9 (ru) 2015-03-27
ES2529175T3 (es) 2015-02-17
CA2769394C (en) 2019-06-25
US9249215B2 (en) 2016-02-02
ES2651762T3 (es) 2018-01-29
RU2012105045A (ru) 2013-09-20
EP2284193A1 (en) 2011-02-16
WO2011018208A1 (en) 2011-02-17
EP2464665A1 (en) 2012-06-20
EP2860191B1 (en) 2017-10-11
RU2529946C2 (ru) 2014-10-10

Similar Documents

Publication Publication Date Title
UA109658C2 (xx) Антитіло проти cgrp
LTPA2021506I1 (lt) Anti-P-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
IL217746A0 (en) Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
SMT201600182B (it) Ligandi sigma per l'uso nella prevenzione e/o nel trattamento del dolore post-operatorio
BRPI1012853A2 (pt) anticorpos humanizados específicos da forma protofibrilar do peptídeo beta-amiloide
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
IL222812B (en) Anti-human trop-2 antibody having antitumor activity in vivo
BRPI0821211A2 (pt) Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
EP2638534A4 (en) Cognitive increase in the presence of distraction and / or interruption
DK2061814T3 (da) Antistoffer og immunokonjugater og anvendelse deraf.
BRPI0923747A2 (pt) "tratamento de safras transgênicas com misturas de fiprolas e cloroniconilas".
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
EP2288324A4 (en) ABSORBENT HYGIENE WITH DISPENSER
CY2022028I1 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
EP2479216A4 (en) EMULSION AND MOLDING SOLVENT WITH THE EMULSION
EP2739244A4 (en) SYSTEMS, METHODS, AND IMPLANTS FOR TREATING PROLAPS OR INCONTINENCE
CR11126A (es) Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2
ITMI20110598A1 (it) Procedimento e apparecchio di comando per l'adattamento del rumore di marcia
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
PL2848258T3 (pl) Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
BRPI0818121A2 (pt) diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização
WO2010117455A3 (en) Human monoclonal antibodies protective against bubonic plaque

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed